Phathom Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

PHAT$5.33+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Deficit

(in thousands, except share amounts)

Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’
	Shares	Amount	Shares	Capital	Deficit	Deficit
Balance at December 31, 2023	57,970,044	$5	19	$855,921	$(928,685)	$(72,759)
401(k) matching contribution	93,736	—	—	712	—	712
Vesting of restricted stock units	340,542	—	—	—	—	—
Stock-based compensation	—	—	—	5,626	—	5,626
ESPP shares issued	119,779	—	—	770	—	770
Net loss	—	—	—	—	(82,852)	(82,852)
Balance at March 31, 2024	58,524,101	$5	19	$863,029	$(1,011,537)	$(148,503)
Vesting of restricted stock units	74,492	—	—	—	—	—
Stock-based compensation	—	—	—	6,099	—	6,099
Issuance of common stock from exercises of stock options	2,432	—	—	21	—	21
Net loss	—	—	—	—	(91,446)	(91,446)
Balance at June 30, 2024	58,601,025	$5	19	$869,149	$(1,102,983)	$(233,829)
401(k) matching contribution	289,853	—	—	2,971	—	2,971
Vesting of restricted stock units	454,003	—	—	—	—	—
Stock-based compensation	—	—	—	5,635	—	5,635
ESPP shares issued	255,602	—	—	1,631	—	1,631
Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net	8,695,652	1	—	121,774	—	121,775
Issuance of common stock from exercises of stock options	27,803	—	—	282	—	282
Net loss	—	—	—	—	(85,577)	(85,577)
Balance at September 30, 2024	68,323,938	$6	19	$1,001,442	$(1,188,560)	$(187,112)

Statements of Stockholders’ Deficit

(in thousands, except share amounts)

Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’
	Shares	Amount	Shares	Capital	Deficit	Equity (Deficit)
Balance at December 31, 2022	41,468,871	$3	19	$652,276	$(727,093)	$(74,814)
401(k) matching contribution	52,130	—	—	456	—	456
Vesting of restricted shares and restricted stock units	414,119	—	—	—	—	—
Stock-based compensation	—	—	—	7,048	—	7,048
ESPP shares issued	121,801	—	—	856	—	856
Issuance of common stock under ATM facility	1,514,219	1	—	14,072	—	14,073
Net loss	—	—	—	—	(37,814)	(37,814)
Balance at March 31, 2023	43,571,140	$4	19	$674,708	$(764,907)	$(90,195)
Vesting of restricted shares and restricted stock units	259,195	—	—	6	—	6
Stock-based compensation	—	—	—	7,253	—	7,253
Issuance of common stock in connection with underwritten public offering, net	12,793,750	1	—	141,389	—	141,390
Issuance of common stock from exercises of stock options	15,000	—	—	111	—	111
Net loss	—	—	—	—	(40,965)	(40,965)
Balance at June 30, 2023	56,639,085	$5	19	$823,467	$(805,872)	$17,600
401(k) matching contribution	83,826	—	—	1,156	—	1,156
Vesting of restricted shares and restricted stock units	9,681	—	—	—	—	—
Stock-based compensation	—	—	—	6,140	—	6,140
ESPP shares issued	75,072	—	—	561	—	561
Issuance of common stock from exercises of stock options	1,421	—	—	13	—	13
Net loss	—	—	—	—	(43,243)	(43,243)
Balance at September 30, 2023	56,809,085	$5	19	$831,337	$(849,115)	$(17,773)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.